secwatch.observer — SEC 8-K summary
======================================

Issuer:     IO Biotech, Inc. (IOBTQ)
CIK:        0001865494
Form:       8-K
Filed at:   2025-09-29T23:59:59+00:00
Accession:  0001193125-25-221704
Event type: regulatory
Sentiment:  negative
Materiality: 0.85
Item codes: 2.05, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA advises IO Biotech not to submit BLA for Cylembio; workforce cut by ~50%
----------------------------------------------------------------------------

- FDA recommends against BLA submission based on IOB-013 trial data (PFS improved but missed statistical significance).
- Company plans new registrational study for first-line advanced melanoma; also engaging European regulators.
- Restructuring reduces workforce ~50%; expects $1.0-1.5M severance charges in Q3 2025.
- Cash runway extended into Q1 2026 to focus on regulatory path for Cylembio.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1865494/000119312525221704/0001193125-25-221704-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1865494/000119312525221704/d940102d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-221704

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer